Bristol-Myers Squibb to present sixteen Orencia (abatacept) data abstracts at The American College of Rheumatology (ACR) 2014 annual meeting
Posted: 13 November 2014 | | No comments yet
Bristol-Myers Squibb Company announced that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology (ACR) taking place from November 14-19, 2014 in Boston, MA…
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology (ACR) taking place from November 14-19, 2014 in Boston, MA. This year’s data reinforce the Company’s commitment to evaluating the use of Orencia in early moderate to severe RA and the potential impact on the course of the disease.
Key presentations include:
- Efficacy results from AVERT (Assessing Very Early Rheumatoid arthritis Treatment), a Phase IIIb trial comparing Orencia in combination with methotrexate (MTX) to MTX alone in patients positive for anti-CCP antibodies with early moderate to severe RA, including MRI imaging outcomes.
- Patient-reported outcomes from AVERT through 12 months of therapy with Orencia in combination with MTX, Orencia alone or MTX alone, and up to 6 months after treatment withdrawal in patients with early moderate to severe RA.
- Studies highlighting real-world Orencia data reinforcing its established safety results.
- An oral presentation highlighting exploratory results from a sub-study of the APPRAISE (Assess the OMERACT-EULAR PDUS score for early signs of improvement of synovitis in RA patients treated with abatacept) trial that was designed to help identify potential biomarkers to predict patient response to the combination of Orencia + MTX in patients with moderate to severe RA.
- Data from the ACTION (Abatacept In routine clinical practice) trial, a real-world prospective study, identifying prognostic factors for long-term retention with Orencia including CCP- and Rheumatoid Factor (RF)- positivity.
“Our exciting data this year underscore our continued commitment to understanding the earlier stages of moderate to severe RA and the potential impact on the course of disease,” said Douglas Manion, M.D., head of Specialty Development, Bristol-Myers Squibb. “The efficacy, safety and real world data we will present help provide valuable insight into treatment response and outcomes in patients with earlier RA.”
The complete list of Bristol-Myers Squibb presentations is below. Abstracts can be accessed on the ACR website at: http://www.acrabstracts.org
Title | Date/Time | |||||
Early Moderate to Severe RA Efficacy Data: AVERT | ||||||
| Stringent Criteria for Low Disease Activity and Remission after 12 | Poster Presentation | |||||
| Months of Treatment, and after Treatment Withdrawal, with Abatacept | November 18 | |||||
| Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in | 8:30 a.m. – 4 p.m. | |||||
| Early Rheumatoid Arthritis | ||||||
| Sustained Improvements in Magnetic Resonance Imaging Outcomes with | Poster Presentation | |||||
| Abatacept Following the Withdrawal of All Treatment in Patients with | November 17 | |||||
| Early Rheumatoid Arthritis | 8:30 a.m. – 4 p.m. | |||||
| Patient-Reported Outcomes Following 12 Months of Therapy with | Poster Presentation | |||||
| Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and | November 18 | |||||
| Up to 6 Months after Treatment Withdrawal in Patients with Early | 8:30 a.m. – 4 p.m. | |||||
| Rheumatoid Arthritis | ||||||
| Predictors of Drug-free Remission Following Treatment with Abatacept | Poster Presentation | |||||
| (in Combination with Methotrexate or as Monotherapy) in Early | November 18 | |||||
| Rheumatoid Arthritis | 8:30 a.m. – 4 p.m. | |||||
| The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope | Poster Presentation | |||||
| Fine Specificity in Patients with Early RA Treated with Abatacept and | November 17 | |||||
| Methotrexate | 8:30 a.m. – 4 p.m. | |||||
| ||||||
| Pregnancy Outcomes Following Exposure to Abatacept During Pregnancy | Oral Presentation | |||||
| November 17 | ||||||
| 2:30 p.m. – 4 p.m. | ||||||
| Identification of Tuberculosis in Rheumatoid Arthritis Patients | Poster Presentation | |||||
| Initiating Therapy with Biologic or Non-Biologic Disease-Modifying | November 16 | |||||
| Anti-Rheumatic Drugs Using Health Insurance Claims Data | 8:30 a.m. – 4 p.m. | |||||
| Healthcare Costs Associated with Serious Infections among Biologic- | Poster Presentation | |||||
| Naïve Rheumatoid Arthritis Patients Initiating First-Line Biologic | November 17 | |||||
| Treatment | 8:30 a.m. – 4 p.m. | |||||
| Comparison of Patient Characteristics, Healthcare Costs, and Biologic | Poster Presentation | |||
| Persistence Between Patients with Rheumatoid Arthritis Initiating | November 16 | |||
| First- or Second-Line Subcutaneous Abatacept, Adalimumab, or | 8:30 a.m. – 4 p.m. | |||
| Etanercept | ||||
| Are Patients With Rheumatoid Arthritis Initiating a TNF Biologic | Poster Presentation | |||
| Comparable to Patients Initiating a Non TNF? | November 18 | |||
| 8:30 a.m. – 4 p.m. | ||||
Potential Prognostic Factors and Predictive Biomarkers | ||||
| Protein Quantification Using Mass Spectrometry Methods to Predict | Oral Presentation | |||
| Response to Abatacept and Methotrexate Combination Therapy in | November 18 | |||
| Rheumatoid Arthritis. | 4:30 p.m. – 6 p.m. | |||
| Prognostic Factors for IV Abatacept Retention in Patients Who Have | Poster Presentation | |||
| Received at Least One Prior Biologic Agent: 2-Year Results from a | November 18 | |||
| Prospective, International, Real-World Study | 8:30 a.m. – 4 p.m. | |||
| Does Body Mass Index Impact Long-Term Retention with Abatacept in | Poster Presentation | |||
| Patients With RA Who Have Received at Least One Prior Biologic Agent? | November 18 | |||
| 2-Year Results from a Real-World, International, Prospective Study | 8:30 a.m. – 4 p.m. | |||
| Do Ultrasound (PDUS) and DAS28 Measure Different Aspects of Disease | Poster Presentation | |||
| Activity? Analyses from the First Prospective International Phase | November 16 | |||
| IIIb Study of PDUS Response in Abatacept-Treated Patients with | 8:30 a.m. – 4 p.m. | |||
| Rheumatoid Arthritis (RA) | ||||
| Analysis of Gene Expression Fluctuation with Abatacept Highlights the | Poster Presentation | |||
| Involvement of the Proteasome Pathway As a Mechanism of Action of | November 17 | |||
| Abatacept in Rheumatoid Arthritis | 8:30 a.m. – 4 p.m. | |||
| Gene Expression Analyses of Abatacept- and Adalimumab-Treated Patients | Poster Presentation | |||
| from the AMPLE Trial | November 17 | |||
| 8:30 a.m. – 4 p.m. | ||||
